BR112016011734A2 - Indóis substituídos e funcionalizados como agentes anti-câncer - Google Patents
Indóis substituídos e funcionalizados como agentes anti-câncerInfo
- Publication number
- BR112016011734A2 BR112016011734A2 BR112016011734A BR112016011734A BR112016011734A2 BR 112016011734 A2 BR112016011734 A2 BR 112016011734A2 BR 112016011734 A BR112016011734 A BR 112016011734A BR 112016011734 A BR112016011734 A BR 112016011734A BR 112016011734 A2 BR112016011734 A2 BR 112016011734A2
- Authority
- BR
- Brazil
- Prior art keywords
- functionalized
- cancer agents
- indoles substituted
- substituted
- indoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
INDÓIS SUBSTITUÍDOS E FUNCIONALIZADOS COMO AGENTES ANTI-CÂNCER. A presente invenção se refere a compostos antitropomiosina, processos para a preparação dos mesmos e métodos para tratar ou prevenir uma doença proliferativa, preferencialmente, câncer, usando os compostos da invenção.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361908285P | 2013-11-25 | 2013-11-25 | |
US201462035671P | 2014-08-11 | 2014-08-11 | |
PCT/AU2014/050372 WO2015074123A1 (en) | 2013-11-25 | 2014-11-25 | Functionalised and substituted indoles as anti-cancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016011734A2 true BR112016011734A2 (pt) | 2017-08-08 |
Family
ID=53178731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016011734A BR112016011734A2 (pt) | 2013-11-25 | 2014-11-25 | Indóis substituídos e funcionalizados como agentes anti-câncer |
Country Status (13)
Country | Link |
---|---|
US (1) | US20170166555A1 (pt) |
EP (1) | EP3074378A4 (pt) |
JP (1) | JP2016538309A (pt) |
KR (1) | KR20160089409A (pt) |
CN (1) | CN105916841A (pt) |
AU (1) | AU2014353893A1 (pt) |
BR (1) | BR112016011734A2 (pt) |
CA (1) | CA2931279A1 (pt) |
IL (1) | IL245673A0 (pt) |
MX (1) | MX2016006707A (pt) |
PH (1) | PH12016500967A1 (pt) |
RU (1) | RU2016122731A (pt) |
WO (1) | WO2015074123A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3148981A4 (en) * | 2014-05-30 | 2017-11-08 | The Trustees of Columbia University in the City of New York | Multivalent ras binding compounds |
SG11201610195UA (en) * | 2014-07-16 | 2017-01-27 | Novogen ltd | Functionalised and substituted indoles as anti-cancer agents |
EP3313399A4 (en) * | 2015-06-29 | 2019-07-24 | NantBio, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING RIT1 |
WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
WO2020048831A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds |
WO2020048830A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds |
WO2020048829A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 3,9-diazaspiro[5.5]undecane compounds |
CN110229091B (zh) * | 2019-06-21 | 2022-11-22 | 天津科技大学 | 具有白三烯a4水解酶抑制作用的1,5-二取代吲哚衍生物及应用 |
MX2022002720A (es) * | 2019-09-05 | 2022-08-10 | Lunan Pharmaceutical Group Corp | Inhibidor de magl, procedimiento de preparacion y uso del mismo. |
KR20230022458A (ko) * | 2020-05-08 | 2023-02-15 | 조지아뮨 엘엘씨 | Akt3 조절제 |
JP2024533748A (ja) * | 2021-09-30 | 2024-09-12 | トロバイオ セラピューティクス ピーティーワイ リミテッド | 置換インドール化合物およびその使用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006067445A2 (en) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
JP2007099641A (ja) * | 2005-09-30 | 2007-04-19 | Tsumura & Co | インドールキノキサリン類化合物、その製造方法およびそれを用いた医薬組成物 |
BRPI0709049A2 (pt) * | 2006-03-22 | 2011-06-21 | Janssen Pharmaceutica Nv | composto inibidor da interação entre mdm2 e p53, composição farmacêutica, processo para preparar a referida composição farmacêutica, uso do composto, combinação, e processo para preparar o referido composto |
CA2644643C (en) * | 2006-03-22 | 2015-05-19 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
US20080280891A1 (en) * | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2008008059A1 (en) * | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
AU2007343063B2 (en) * | 2007-01-08 | 2011-02-17 | Suven Life Sciences Limited | 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands |
CN102036953B (zh) * | 2008-03-24 | 2015-05-06 | 诺华股份有限公司 | 基于芳基磺酰胺的基质金属蛋白酶抑制剂 |
DK2488486T3 (da) * | 2009-10-13 | 2019-11-18 | Ligand Pharm Inc | Småmolekylære forbindelser der efterligner hæmapoetisk vækstfaktor og anvendelse deraf |
WO2012068406A2 (en) * | 2010-11-18 | 2012-05-24 | Ligand Pharmaceuticals Incorporated | Use of hematopoietic growth factor mimetics |
KR20130106186A (ko) * | 2012-03-19 | 2013-09-27 | 한국과학기술원 | 아자인돌 유도체 화합물, 이를 포함하는 Trk 저해제 조성물 및 Trk와 관련된 질환의 예방 및 치료용 약학 조성물 |
WO2015074124A1 (en) * | 2013-11-25 | 2015-05-28 | Novogen ltd | Functionalised and substituted indoles as anti-cancer agents |
SG11201610195UA (en) * | 2014-07-16 | 2017-01-27 | Novogen ltd | Functionalised and substituted indoles as anti-cancer agents |
-
2014
- 2014-11-25 BR BR112016011734A patent/BR112016011734A2/pt not_active Application Discontinuation
- 2014-11-25 KR KR1020167015985A patent/KR20160089409A/ko not_active Application Discontinuation
- 2014-11-25 MX MX2016006707A patent/MX2016006707A/es unknown
- 2014-11-25 JP JP2016534990A patent/JP2016538309A/ja active Pending
- 2014-11-25 WO PCT/AU2014/050372 patent/WO2015074123A1/en active Application Filing
- 2014-11-25 EP EP14864170.7A patent/EP3074378A4/en not_active Withdrawn
- 2014-11-25 CA CA2931279A patent/CA2931279A1/en not_active Abandoned
- 2014-11-25 US US15/039,017 patent/US20170166555A1/en not_active Abandoned
- 2014-11-25 RU RU2016122731A patent/RU2016122731A/ru unknown
- 2014-11-25 CN CN201480071201.9A patent/CN105916841A/zh active Pending
- 2014-11-25 AU AU2014353893A patent/AU2014353893A1/en not_active Abandoned
-
2016
- 2016-05-17 IL IL245673A patent/IL245673A0/en unknown
- 2016-05-24 PH PH12016500967A patent/PH12016500967A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12016500967A1 (en) | 2016-06-20 |
RU2016122731A (ru) | 2018-01-09 |
IL245673A0 (en) | 2016-06-30 |
US20170166555A1 (en) | 2017-06-15 |
CA2931279A1 (en) | 2015-05-28 |
KR20160089409A (ko) | 2016-07-27 |
EP3074378A4 (en) | 2017-05-10 |
WO2015074123A1 (en) | 2015-05-28 |
CN105916841A (zh) | 2016-08-31 |
EP3074378A1 (en) | 2016-10-05 |
MX2016006707A (es) | 2016-11-29 |
AU2014353893A1 (en) | 2016-06-09 |
JP2016538309A (ja) | 2016-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016011734A2 (pt) | Indóis substituídos e funcionalizados como agentes anti-câncer | |
CO2017000065A2 (es) | Indoles funcionalizados y sustituidos como agentes anti-cáncer | |
LTC2822953I2 (lt) | Makrocikliniai dariniai, skirti proliferacinių ligų gydymui | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
ECSP16083602A (es) | Derivados de quinolina como inhibidores smo | |
BR112016004194A8 (pt) | compostos úteis como imunomoduladores | |
CL2016002548A1 (es) | Derivados de tubulisina | |
CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
BR112016022785A2 (pt) | composto, composição farmacêutica, kit farmacêutico para tratar um câncer, e, métodos de tratamento de uma doença e/ou uma condição e/ou um distúrbio e de síntese de um composto | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
EA201690713A1 (ru) | Гетероциклические соединения и их применения | |
CL2015003735A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
BR112016010169A2 (pt) | anticorpos anticlaudina e métodos de uso | |
BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
EA201692100A8 (ru) | Новые антитела против rnf43 и способы их применения | |
MX2016002574A (es) | Nuevos moduladores del homologo 6 (sez6) y metodos de uso. | |
EA201791203A1 (ru) | ЛЕКАРСТВЕННЫЙ КОНЪЮГАТ АНТИТЕЛА ПРОТИВ с-МЕТ | |
CL2015000926A1 (es) | Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios. | |
BR112017012005A2 (pt) | compostos orgânicos | |
CY1122403T1 (el) | Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης | |
EA201791249A1 (ru) | Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний | |
BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
EA201690294A1 (ru) | Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов | |
BR112017016333A2 (pt) | compostos anticâncer | |
CL2015003431A1 (es) | Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |